Ovarian Cancer Drugs Market Growth Rate, Statistics, Segment and Forecast| Roche, Amgen, Boehringer Ingelheim
Ovarian
cancer is a type of cancer that affects the female reproductive organs. In
2012, the World Health Organization reported that 2,38,700 women were diagnosed
with ovarian cancer. The report examines the demand for ovarian cancer
medications, which is expected to contribute to the market's growth. It focuses
on both generic and brand-name medications used to treat ovarian cancer, as
well as their commercial impact.
The rising
incidence of ovarian cancer is driving the market. The demand for more effective
treatment alternatives is propelling the industry forward. While generics like
paclitaxel and carboplatin now dominate the market, medications like
Bevacizumab (Avastin) and Pazopanib (Votrient) are projected to drive growth.
This market faces a difficulty in developing medications with higher efficacy.
The development of novel medications to treat ovarian cancer is a potential for
this market.
The ovarian cancer drugs market is divided into four regions: North America, Europe, Asia
Pacific, and Latin America and the Caribbean. Because of the high prevalence of
ovarian cancer in North America, it is the most lucrative market. According to
the American Cancer Society, 21,980 women in the United States will be
diagnosed with ovarian cancer in 2014. Because of the high incidence of ovarian
cancer in Europe, it is the second largest market.
The drugs
used to treat ovarian cancer include Paclitaxel,
Cisplatin, Adriamycin PFS (Doxorubicin Hydrochloride), Carboplatin,
Cyclophosphamide, Platinol (Cisplatin), Paraplatin (Carboplatin), Evacet
(Doxorubicin Hydrochloride Liposome), Cytoxan (Cyclophosphamide), Paraplat
(Carboplatin), Taxol (Paclitaxel) (Cyclophosphamide).
Roche,
Amgen, Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, and others are among
the firms involved. Roche's medicine Avastin (bevacizumab) was approved by the
European Union in December 2011 for use in the treatment of ovarian cancer in
combination with carboplatin and paclitaxel.

Comments
Post a Comment